172 related articles for article (PubMed ID: 36601880)
121.
Okamura R; Kato S; Lee S; Jimenez RE; Sicklick JK; Kurzrock R
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32111729
[TBL] [Abstract][Full Text] [Related]
122. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
Li J; Wang W; Zhang Y; Cieślik M; Guo J; Tan M; Green MD; Wang W; Lin H; Li W; Wei S; Zhou J; Li G; Jing X; Vatan L; Zhao L; Bitler B; Zhang R; Cho KR; Dou Y; Kryczek I; Chan TA; Huntsman D; Chinnaiyan AM; Zou W
J Clin Invest; 2020 May; 130(5):2712-2726. PubMed ID: 32027624
[TBL] [Abstract][Full Text] [Related]
123. Pan-cancer analysis of
Jiang T; Chen X; Su C; Ren S; Zhou C
J Cancer; 2020; 11(4):776-780. PubMed ID: 31949479
[No Abstract] [Full Text] [Related]
124. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
Hu G; Tu W; Yang L; Peng G; Yang L
Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
[TBL] [Abstract][Full Text] [Related]
125. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
Yao J; Gong Y; Zhao W; Han Z; Guo S; Liu H; Peng X; Xiao W; Li Y; Dang S; Liu G; Li L; Huang T; Chen S; Song L
Sci Rep; 2019 Oct; 9(1):15767. PubMed ID: 31673068
[TBL] [Abstract][Full Text] [Related]
126. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
[TBL] [Abstract][Full Text] [Related]
127. Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1.
Lee JS; Ruppin E
JAMA Oncol; 2019 Nov; 5(11):1614-1618. PubMed ID: 31436822
[TBL] [Abstract][Full Text] [Related]
128. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.
Wang F; Zhao Q; Wang YN; Jin Y; He MM; Liu ZX; Xu RH
JAMA Oncol; 2019 Oct; 5(10):1504-1506. PubMed ID: 31415061
[TBL] [Abstract][Full Text] [Related]
129. Host tissue determinants of tumour immunity.
Salmon H; Remark R; Gnjatic S; Merad M
Nat Rev Cancer; 2019 Apr; 19(4):215-227. PubMed ID: 30867580
[TBL] [Abstract][Full Text] [Related]
130. The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer.
Rampias T; Karagiannis D; Avgeris M; Polyzos A; Kokkalis A; Kanaki Z; Kousidou E; Tzetis M; Kanavakis E; Stravodimos K; Manola KN; Pantelias GE; Scorilas A; Klinakis A
EMBO Rep; 2019 Mar; 20(3):. PubMed ID: 30665945
[TBL] [Abstract][Full Text] [Related]
131. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Samstein RM; Lee CH; Shoushtari AN; Hellmann MD; Shen R; Janjigian YY; Barron DA; Zehir A; Jordan EJ; Omuro A; Kaley TJ; Kendall SM; Motzer RJ; Hakimi AA; Voss MH; Russo P; Rosenberg J; Iyer G; Bochner BH; Bajorin DF; Al-Ahmadie HA; Chaft JE; Rudin CM; Riely GJ; Baxi S; Ho AL; Wong RJ; Pfister DG; Wolchok JD; Barker CA; Gutin PH; Brennan CW; Tabar V; Mellinghoff IK; DeAngelis LM; Ariyan CE; Lee N; Tap WD; Gounder MM; D'Angelo SP; Saltz L; Stadler ZK; Scher HI; Baselga J; Razavi P; Klebanoff CA; Yaeger R; Segal NH; Ku GY; DeMatteo RP; Ladanyi M; Rizvi NA; Berger MF; Riaz N; Solit DB; Chan TA; Morris LGT
Nat Genet; 2019 Feb; 51(2):202-206. PubMed ID: 30643254
[TBL] [Abstract][Full Text] [Related]
132. Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.
Wang Z; Zhao J; Wang G; Zhang F; Zhang Z; Zhang F; Zhang Y; Dong H; Zhao X; Duan J; Bai H; Tian Y; Wan R; Han M; Cao Y; Xiong L; Liu L; Wang S; Cai S; Mok TSK; Wang J
Cancer Res; 2018 Nov; 78(22):6486-6496. PubMed ID: 30171052
[TBL] [Abstract][Full Text] [Related]
133. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Shen J; Ju Z; Zhao W; Wang L; Peng Y; Ge Z; Nagel ZD; Zou J; Wang C; Kapoor P; Ma X; Ma D; Liang J; Song S; Liu J; Samson LD; Ajani JA; Li GM; Liang H; Shen X; Mills GB; Peng G
Nat Med; 2018 May; 24(5):556-562. PubMed ID: 29736026
[TBL] [Abstract][Full Text] [Related]
134. DNA Repair Deficiency and Immunotherapy Response.
Mouw KW; D'Andrea AD
J Clin Oncol; 2018 Jun; 36(17):1710-1713. PubMed ID: 29683789
[No Abstract] [Full Text] [Related]
135. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Seidel JA; Otsuka A; Kabashima K
Front Oncol; 2018; 8():86. PubMed ID: 29644214
[TBL] [Abstract][Full Text] [Related]
136. The Immune Landscape of Cancer.
Thorsson V; Gibbs DL; Brown SD; Wolf D; Bortone DS; Ou Yang TH; Porta-Pardo E; Gao GF; Plaisier CL; Eddy JA; Ziv E; Culhane AC; Paull EO; Sivakumar IKA; Gentles AJ; Malhotra R; Farshidfar F; Colaprico A; Parker JS; Mose LE; Vo NS; Liu J; Liu Y; Rader J; Dhankani V; Reynolds SM; Bowlby R; Califano A; Cherniack AD; Anastassiou D; Bedognetti D; Mokrab Y; Newman AM; Rao A; Chen K; Krasnitz A; Hu H; Malta TM; Noushmehr H; Pedamallu CS; Bullman S; Ojesina AI; Lamb A; Zhou W; Shen H; Choueiri TK; Weinstein JN; Guinney J; Saltz J; Holt RA; Rabkin CS; ; Lazar AJ; Serody JS; Demicco EG; Disis ML; Vincent BG; Shmulevich I
Immunity; 2018 Apr; 48(4):812-830.e14. PubMed ID: 29628290
[TBL] [Abstract][Full Text] [Related]
137. Cancer immunotherapy using checkpoint blockade.
Ribas A; Wolchok JD
Science; 2018 Mar; 359(6382):1350-1355. PubMed ID: 29567705
[TBL] [Abstract][Full Text] [Related]
138. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.
Li T; Fan J; Wang B; Traugh N; Chen Q; Liu JS; Li B; Liu XS
Cancer Res; 2017 Nov; 77(21):e108-e110. PubMed ID: 29092952
[TBL] [Abstract][Full Text] [Related]
139. DNA Damage and Repair Biomarkers of Immunotherapy Response.
Mouw KW; Goldberg MS; Konstantinopoulos PA; D'Andrea AD
Cancer Discov; 2017 Jul; 7(7):675-693. PubMed ID: 28630051
[TBL] [Abstract][Full Text] [Related]
140. Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Gibney GT; Weiner LM; Atkins MB
Lancet Oncol; 2016 Dec; 17(12):e542-e551. PubMed ID: 27924752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
